COVID-19 therapeutics reminders: Paxlovid & Evusheld

July 14, 2022

Paxlovid Emergency Use Authorization (EUA): The Food and Drug Administration (FDA) and the Washington State Department of Health (DOH) are alerting providers to changes to the EUA for Paxlovid, most recently updated July 6, 2022.

Evusheld dosing and shelf life: On June 29, the FDA revised the recommended adult and pediatric Evusheld doses to repeated dosing every six months, with doses of tixagevimab and cilgavimab if ongoing protection is needed. The FDA also extended the authorized shelf life from 18 months to 24 months for specific lots of Evusheld, as long as the batches are unopened and in compliance with storage requirements. The relevant lot numbers and extended expiration dates are listed in “Table 1” online here.

Additional resources, guidance and previous updates are available on WSHA’s 2022 COVID-19 Therapeutics webpage. For questions related to therapeutics or these resources, please reach out to the Washington State Department of Health Medical Countermeasure Team at or WSHA Senior Director Tina Seery at


Contact Us

Washington State Hospital Association
999 Third Avenue
Suite 1400
Seattle, WA 98104

Map / Directions

206.281.7211 phone
206.283.6122 fax

Staff List